Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted Therapy

NCT06083974 | Completed

• 1 other identifier: Anti_EGFR -Targeted therapy
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

Colorectal cancer ranks the second lethal cancer and third prevalent malignant tumour worldwide, Despite of different odern modalities for diagnosis,large number of cases diagnosed at metastatic advanced stage . New treatment approach has been discovered habe been discovered making a huge revolution in metastatic colorectal cancer represented by targeted therapy including anti\_EGFR ,anti\_angiogenic and kinase inhibitors .

Conditions

Metastatic Colorectal Adenocarcinoma

Keywords

EGFR, Targeted therapy ,metastatic colorectal cancer

Outcome Measures

Primary Outcomes (1)

• OS and DFS of patients with metastatic colorectal cancer patients received anti_EGFR targeted therapy

  Evaluation of anti-EGFR targeted therapy on metastatic cancer rectum and left colon and factors affecting response to treatment

  Anti_EGFR targeted therapy in assuit university hospitals from 2015 to 2022

Secondary Outcomes (1)

• Response rate (RR) in patients received chemotherapy only or with combination with targeted therapy.

  The response of patients to EGFR targeted therapy in AUH at period from 2015 to 2022

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with left colon and rectum cancer of stage four received target therapy anti\_EGFR targeted therapy

You may qualify if:

• age above 18
• Both sex
• Performance status zero to one according to ECOG scale system
• Histo-pathologial diagnosis adenocarcinoma of left colon or rectum.
• Patients diagnosed with left colon and rectal cancer.
• Patients eligible to receive chemotherapy (with renal and liver chemistry, and normal CBC.
• Patients diagnosed with metastatic stage.
• K-RAS wild type.

You may not qualify if:

• Second malignancy
• Histo-pathological types other than adenocarcinoma.
• Right colon cancer patients.
• Patients refused receiving anti\_EGFR targeted therapy.
• Patients with any abnormalities preventing to receive chemotherapy.
• Early stages of colorectal cancer.
• K-RAS mutant type.

Sponsors & Collaborators

• Assiut University: lead

Related Links

• Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
• Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cance
• tion between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer
• The biology of VEGF and its receptor
• Advances and new perspectives in the treatment of metastatic colon cancer

Study Officials

• Samir E Shehata, Professor

  Assiut University

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal investigator1

Study Record Dates

• First Submitted: October 4, 2023
• First Posted: October 16, 2023
• Study Start: January 1, 2015
• Primary Completion: December 30, 2022
• Study Completion: December 30, 2022
• Last Updated: October 16, 2023

Record last verified: 2023-10

Data Sharing

• IPD Sharing: Will not share